Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results

Core Insights - Neurocrine Biosciences, Inc. has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for February 11, 2026, at 1:30 p.m. Pacific Time [1][4] - The company is focused on developing treatments for neurological, psychiatric, endocrine, and immunological disorders, with a diverse portfolio that includes FDA-approved treatments and a robust pipeline [2] Company Overview - Neurocrine Biosciences is a leading biopharmaceutical company dedicated to discovering and developing life-changing treatments for patients with under-addressed conditions [2] - The company's portfolio includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids, with some products developed in collaboration with AbbVie [2] - The company has been applying its insights into neuroscience for three decades to address complex conditions and aims to ease the burden of debilitating diseases [2]